2023 World Conference on Lung Cancer (Posters)-EP11.04. Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

EP11.04. Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

The session at the World Conference on Lung Cancer in 2023 will focus on metastatic non-small cell lung cancer (NSCLC) and the use of immunotherapy. The presentation will discuss a study investigating the use of trilaciclib, a myeloprotective agent, in combination with chemotherapy and the immune checkpoint inhibitor tislelizumab as a first-line treatment for advanced squamous NSCLC. <br /><br />Chemotherapy combined with immune checkpoint inhibitors is currently the standard treatment for advanced squamous NSCLC, regardless of the expression levels of a specific biomarker. However, chemotherapy often leads to myelosuppression, which can result in a reduction in key blood cell counts and subsequent side effects that affect patients' quality of life and survival rates. Trilaciclib, a CDK4/6 inhibitor, has been shown to be effective in protecting blood cell counts in patients with small cell lung cancer undergoing chemotherapy and has been approved for this use by regulatory agencies. <br /><br />The study is a phase 2 clinical trial that will randomly assign 132 patients with advanced squamous NSCLC to receive or not receive trilaciclib in combination with chemotherapy and tislelizumab. The primary endpoint of the study is the incidence of grade 3 neutrophil count decrease during the initial treatment period. Other myeloprotective indicators, including platelet reduction and anemia, as well as anti-tumor efficacy measures such as objective response rate, progression-free survival, and overall survival, will also be evaluated. If patients require additional chemotherapy after disease progression, trilaciclib will be provided to observe its myeloprotective effect in second-line treatment. <br /><br />The study is set to begin recruiting patients in mainland China in May 2023. The findings from this study will contribute to our understanding of the use of trilaciclib in combination with chemotherapy and immunotherapy as a potential treatment option for advanced squamous NSCLC.

Asset Subtitle

Yongsheng Wang

Meta Tag

Speaker Yongsheng Wang

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

World Conference on Lung Cancer

metastatic non-small cell lung cancer

immunotherapy

trilaciclib

myeloprotective agent

chemotherapy

immune checkpoint inhibitor

squamous NSCLC

CDK4/6 inhibitor

phase 2 clinical trial